Accordingly, several studies using pharmacological NRF2 activators suggested a protective role of NRF2 activation against obesity and insulin resistance (Yu et al., 2011; He et al., 2012; Bahadoran et al., 2013). This evidence concerns the gene NFE2L2 and obesity due to melanocortin 4 receptor deficiency.